Celiprolol Hydrochloride Capsules

Pharmacological action: This product is a highly selective β-receptor blocker that dilates blood vessels and lowers blood pressure by blocking β1 receptors. This product highly selectively binds to β1 receptors on the myocardial cell membrane, and its affinity is 20 to 30 times stronger than that of bronchial and vascular smooth muscle β2 receptors. It can reduce heart rate and cardiac output during rest and exercise, reduce systolic blood pressure during exercise, and inhibit tachycardia induced by isoproterenol. For healthy people, this product cannot reverse the vasodilatory effect of isoproterenol mediated by β2 receptors. This product has intrinsic sympathomimetic activity, does not increase respiratory resistance, dilates peripheral blood vessels, and improves blood circulation. This product has no membrane stabilizing effect, nor does it inhibit myocardial contractility. It is less likely to cause sinus bradycardia than other β-receptor blockers without endogenous sympathomimetic activity. This product can pass through the placental barrier. Non-clinical toxicology study: After a single oral or intravenous administration of celiprol hydrochloride to Kunming mice, the animal symptoms mainly showed sedation, startle, ataxia, skin flushing, decreased activity, etc. The above symptoms completely disappeared within 7 days. The LD50 of the drug for oral and intravenous injection is 1190.2 and 41.7 mg/kg respectively.

The main component of this product is celiprolol hydrochloride, the chemical name is 3-[3-acetyl-4-(3-tert-butylamino-2-hydroxy-propoxy)-phenyl]-1,1-diethylurea hydrochloride, the chemical structure is as follows: Molecular formula: C20H33N3O4·HCl Molecular weight: 415.96

This product is a capsule, and the contents are white granular powder or powder.

Mild to moderate hypertension.

Oral administration, 1 to 3 tablets (100 to 300 mg) at a time, once a day, in the morning or as directed by a doctor.

There may be headache, dizziness, fatigue, drowsiness, somnolence and nausea. Generally, the reaction is mild. Palpitations and tremors may occur occasionally. Usually, there is no need to stop the drug. Depression and allergic reactions are rare. If bronchospasm, rash and other side effects related to beta-blockers occur, the drug should be discontinued.

Precautions for children: This product is not recommended. Precautions for pregnancy and lactation: This product can pass through the placental barrier, so it is not recommended.

When used in combination with adrenergic neuron blocking drugs such as reserpine, their effects are additive, and sometimes postural hypotension and bradycardia, even dizziness and syncope, may occur. Both verapamil and beta-blockers can slow down A-V conduction and inhibit myocardial contractility, but their mechanisms of action are different. When switching from verapamil to this product or from this product to verapamil, a drug withdrawal period is recommended. If continuous administration is required, ECG monitoring should be used at the beginning. Patients with existing conduction abnormalities should not use the two drugs together. Be careful when using it in combination with Class I antiarrhythmic drugs such as proglumide. Food can reduce the bioavailability of this product, and it may also reduce the bioavailability of this product when used in combination with chlorthalidone and hydrochlorothiazide.

Keep away from light and store in sealed container.

0.1g

36 months

FuJian Pacific Pharmaceutical Co., Ltd.

• Founded in:

  1992-10-14

• Address:

  No. 1, Yatai Road, Qingmeng Park, Quanzhou Economic and Technological Development Zone, Fujian Province

• Tax NO.:

  91350502611536656Q

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view